Ani Pharmaceuticals (ANIP) Cash & Current Investments (2010 - 2026)

Ani Pharmaceuticals (ANIP) has 17 years of Cash & Current Investments data on file, last reported at $311.2 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments rose 107.7% year-over-year to $311.2 million; the trailing twelve-month figure through Mar 2026 stood at $311.2 million (up 107.7% YoY), and the FY2025 full-year result was $285.6 million, up 97.12% from the prior year.
• Cash & Current Investments grew to $311.2 million in Q1 2026, from $285.6 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $311.2 million in Q1 2026 to a low of $53.2 million in Q4 2022.
• A 5-year average of $170.2 million and a median of $161.7 million in 2023 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments sank 49.45% in 2022 and soared 315.38% in 2023, its largest moves.
• Tracing ANIP's Cash & Current Investments over 5 years: stood at $53.2 million in 2022, then jumped by 315.38% to $221.1 million in 2023, then plunged by 34.47% to $144.9 million in 2024, then jumped by 97.12% to $285.6 million in 2025, then climbed by 8.96% to $311.2 million in 2026.
• Business Quant data shows ANIP's Cash & Current Investments at $311.2 million in Q1 2026, $285.6 million in Q4 2025, and $262.6 million in Q3 2025.